Italy was the first European country to be affected by the SARS-CoV-2 pandemic. In this scenario, we had to face a new clinical approach in our Pediatric Rheumatology Unit for the management of patients affected by juvenile idiopathic arthritis (JIA)-associated uveitis. During the lockdown (phase 1), the weekly outpatient clinic was discontinued and telephone consultations were set up. A toll-free telephone number was instituted for emergencies. None of our children with JIA-associated uveitis was advised to stop the ongoing immunosuppressant systemic therapy. We had no cases of COVID-19 infection and uveitis activity was under control in all but two out of 125 patients, which was comparable with the pre-COVID-19 situation. During phase 2 of the pandemic, hospital and ambulatory rearrangements were made to minimize the risk of SARS-CoV-2 infection. Overall, during the first 4 weeks of phase 2, we did not notice an increased number of patients with uveitis activity.
Management of Juvenile Idiopathic Arthritis-associated Uveitis during the COVID-19 Pandemic in a Pediatric Referral Center in Lombardy / E. Miserocchi, C. Giuffre, G.M. Modorati, R. Cimaz. - In: OCULAR IMMUNOLOGY AND INFLAMMATION. - ISSN 0927-3948. - 28:8(2020 Nov 16), pp. 1305-1307.
|Titolo:||Management of Juvenile Idiopathic Arthritis-associated Uveitis during the COVID-19 Pandemic in a Pediatric Referral Center in Lombardy|
CIMAZ, ROLANDO (Ultimo)
|Parole Chiave:||COVID-19; JIA-associated uveitis; juvenile idiopathic arthritis; pediatric uveitis; SARS-CoV-2;|
|Settore Scientifico Disciplinare:||Settore MED/16 - Reumatologia|
|Data di pubblicazione:||16-nov-2020|
|Data ahead of print / Data di stampa:||ago-2020|
|Digital Object Identifier (DOI):||http://dx.doi.org/10.1080/09273948.2020.1800752|
|Appare nelle tipologie:||01 - Articolo su periodico|